• 1
    Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004;110:e82292.
  • 2
    Taylor J. 2012 ESC Guidelines on acute myocardial infarction (STEMI). Eur Heart J 2012;33:25012.
  • 3
    Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357:112135.
  • 4
    Roubille F, Combes S, Leal-Sanchez J, Barrere C, Cransac F, Sportouch-Dukhan C et al. Myocardial expression of a dominant-negative form of Daxx decreases infarct size and attenuates apoptosis in an in vivo mouse model of ischemia/reperfusion injury. Circulation 2007;116:270917.
  • 5
    Vincent A, Gahide G, Sportouch-Dukhan C, Covinhes A, Franck-Miclo A, Roubille F et al. Down-regulation of the transcription factor ZAC1 upon pre- and postconditioning protects against I/R injury in the mouse myocardium. Cardiovasc Res 2012;94:3518.
  • 6
    Zak R. Development and proliferative capacity of cardiac muscle cells. Circ Res 1974;35(Suppl. 2):1726.
  • 7
    Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 2003;108:1395403.
  • 8
    Roubille F, Busseuil D, Merlet N, Kritikou E, Rhéaume E, Tardif J-C. Investigational drugs targeting cardiac fibrosis. Expert Rev Cardiovasc Ther 2013 In press.
  • 9
    Dignat-George F, Blann A, Sampol J. Circulating endothelial cells in acute coronary syndromes. Blood 2000;95:728.
  • 10
    Bonello L, Laine M, Baumstarck K, Fernandez J, Maillard L, Peyrol M et al. A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity. Int J Cardiol 2013;168:42448.
  • 11
    Kin H, Zhao ZQ, Sun HY, Wang NP, Corvera JS, Halkos ME et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 2004;62:7485.
  • 12
    Roubille F, Franck-Miclo A, Covinhes A, Lafont C, Cransac F, Combes S et al. Delayed postconditioning in the mouse heart in vivo. Circulation 2011;124:13306.
  • 13
    Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet 2013;381:16675.
  • 14
    Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 2011;57:891903.
  • 15
    Kang KT, Coggins M, Xiao C, Rosenzweig A, Bischoff J. Human vasculogenic cells form functional blood vessels and mitigate adverse remodeling after ischemia reperfusion injury in rats. Angiogenesis 2013;16:77384.
  • 16
    Galaup A, Gomez E, Souktani R, Durand M, Cazes A, Monnot C et al. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Circulation 2012;125:1409.
  • 17
    Tardif JC, Tanguay JF, Wright SS, Duchatelle V, Petroni T, Gregoire JC et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol 2013;61:204855.
  • 18
    Garcia-Dorado D, Andres-Villarreal M, Ruiz-Meana M, Inserte J, Barba I. Myocardial edema: a translational view. J Mol Cell Cardiol 2012;52:9319.